BioSpace News Archive

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that it will present results from a study evaluating the prevalence of phosphatidylinositol-3-kinase (PI3K)/AKT/PTEN pathway alterations and co-alterations in patients with different subtypes of breast cancer.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today the launch of their Vector Smart™ NAM-e (North American Mosquito-East) multiplex test, which detects the eastern equine encephalitis (EEE) virus among mosquito populations, along with West Nile virus (WNV) and St. Louis encephalitis (SLE).

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced that it will issue financial results for its fiscal year ended September 30, 2019 on Monday December 16, 2019.

Genetic Technologies Limited is pleased to announce the full commissioning of its Australian Laboratory for the provisioning of its generation 3 breast cancer test with sales to commence in Q1, 2020.

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Development.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to commence a Phase 2 expansion cohort based on encouraging clinical activity and a well-tolerated safety profile observed to date in the ongoing Phase 1 dose escalation trial of SNDX-6352 in patients with chronic graft versus host disease (cGVHD).

Inscripta, Inc., today announced the company has raised $125 million in a Series D financing with support from the company’s existing investors and new investors JS Capital Management LLC and Oak HC/FT.

Quellis Biosciences Inc., an emerging biopharmaceutical company focused on discovering best-in-class new molecules to treat serious rare diseases, today announced its emergence from stealth operations and that it has closed a $17 million Series A financing led by the Perceptive Xontogeny Venture Fund (PXV Fund).

Nihon Kohden announced the launch of its Life Scope® SVM-7200 Series vital signs monitor, a monitor designed for outpatient facilities and beds that traditionally are not continuously monitored.

Diverse Biotech, Inc. www.diversebiotech.com has announced it has successfully synthesized and progressed into pre-clinical testing its first two new chemical entities developed using its proprietary CuSP-C2 technology platform.